Parameters for measurement of oxidative stress in diabetes mellitus: Applicability of enzyme-linked immunosorbent assay for clinical evaluation

Journal of Investigative Medicine

Volumn 53, Issue 4, 2005, Pages 167-175

  Noiri, Eisei ^a   Tsukahara, Hirokazu ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

Advanced glycation end products; Diabetes mellitus; Enzyme linked immunosorbent assay; Fatty acid binding protein; Lipid peroxide; Nitric oxide; Oxidative stress; Peroxynitrite; Thioredoxin

Indexed keywords

REACTIVE OXYGEN METABOLITE; SCHIFF BASE;

AMADORI REARRANGEMENT; DIABETES MELLITUS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCATION; HIGH THROUGHPUT SCREENING; HUMAN; HYPERGLYCEMIA; MEASUREMENT; OXIDATIVE STRESS; PARAMETER; RELIABILITY; REVIEW; VASCULAR DISEASE;

EID: 20444425288     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2005.00403     Document Type: Review

References (61)

1. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994;70:138-51.
2. Suzuki D, Miyata T. Carbonyl stress in the pathogenesis of diabetic nephropathy. Intern Med 1999;38:309-14.
3. Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions: implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. I Clin Invest 1997;100:2995-3004.
4. Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissue. Am J Pathol 1993;143:1699-712.
5. Araki N, Ueno N, Chakrabarti B, et al. Immunohistochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with age. I Biol Chem 1992;267:10211-4.
6. Ikeda K, Higashi T, Sano H, et al. N-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996;35:8075-83.
7. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-42.
8. Makita Z, Vlassara H, Rayfield E, et al. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 1992;258:651-3.
9. Kislinger T, Fu C, Huber B, et al. N-(Carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathyways and modulate gene expression. J Biol Chem 1999;274:31740-9.
10. Degenhardt TP, Grass L, Reddy S, et al. The serum concentration of the advanced glycation end-product N-(carboxymethyl)lysine is increased in uremia. Kidney Int 1997;52:1064-7.
11. Papanastasiou P, Grass L, Rodela H, et al. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994;46:216-22.
12. Buss H, Chan TP, Sluis KB, et al. Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 1997;23:361-6.
13. Himmelfarb J, McMonagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 2001;60:358-63.
14. Schalkwijk CG, Chaturvedi N, Twaafhoven H, et al. Amadorialbumin correlates with microvascular complications and precedes nephropathy in type 1 diabetic patients. Eur J Clin Invest 2002;32:500-6.
15. Taneda S, Monnier VM. ELISA of pentosidine, an advanced glycation end product, in biological specimens. Clin Chem 1994;40:1766-73.
16. Izuhara Y, Miyata T, Ueda Y, et al. A sensitive and specific ELISA for plasma pentosidine. Nephrol Dial Transplant 1999;14:576-80.
17. Shimoike T, Inoguchi T, Umeda F, et al. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 2000;49:1030-5.
18. Berg TJ, Bangstad HJ, Torjesen PA, et al. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 1997;46:661-5.
19. Satoh K, Yamada S, Koike Y, et al. A one-hour enzyme-linked immunosorbent assay for quantitation of acrolein- and hydroxynonenal-modified proteins by epitope-bound casein matrix method. Anal Biochem 1999;270:323-8.
20. Toyokuni S, Yamada S, Kashima M, et al. Serum 4-hydroxy-2-nonenal- modified albumin is elevated in patients with type 2 diabetes mellitus. Antiox Redox Signal 2000;2:681-5.
21. Uchida K, Kanematsu M, Sakai K, et al. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci U S A 1998;95:4882-7.
22. Tsukahara H, Sekine K, Uchiyama M, et al. Formation of advanced glycosylation end products and oxidative stress in young patients with type 1 diabetes. Pediatr Res 2003;54:419-24.
23. Noiri E, Yamada S, Nakao A, et al. Serum protein acrolein adducts: utility in detecting oxidant stress in hemodialysis patients and reversal using a vitamin E-bonded hemodialyzer. Free Radic Biol Med 2002;33:1651-6.
24. Bucala R, Makita Z, Koschinsky T, et al. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 1993;90:6434-8.
25. Kume S, Takeya M, Mori T, et al. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995;147:654-7.
26. Castellani RJ, Harris PL, Sayre LM, et al. Active glycation in neurofibrillary pathology of Alzheimer disease: N-(carboxymethyl)lysine and hexitol-lysine. Free Radic Biol Med 2001;31:175-80.
27. Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 1999;49:91-102.
28. Dandona P, Thusu K, Cook S, et al. Oxidative damage to DNA in diabetes mellitus. Lancet 1996;347:444-5.
29. Leinonen J, Lehtimäki T, Toyokuni S, et al. New biomarker evidence of oxidative DNA damage in patients with non-insulin-dependent diabetes mellitus. FEBS Lett 1997;417:150-2.
30. Kanauchi M, Nishioka H, Hashimoto T. Oxidative DNA damage and tubulointerstitial injury in diabetic nephropathy. Nephron 2002;91:327-9.
31. Nordberg J, Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 2001;31:1287-312.
32. Masutani H, Yodoi J. Thioredoxin. Overview. Methods Enzymol 2002;347:279-86.
33. Hotta M, Tashiro F, Ikegami H, et al. Pancreatic beta cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J Exp Med 1998;188:1445-51.
34. Kakisaka Y, Nakashima T, Sumida Y, et al. Elevation of serum thioredoxin levels in patients with type 2 diabetes. Horm Metab Res 2002;34:160-4.
35. Stocker R, Yamamoto Y, McDonagh AF, et al. Bilirubin is an antioxidant of possible physiological importance. Science 1987;235:1043-6.
36. Yoshida R, Ogawa Y, Shioji I, et al. Urinary 8-oxo-7, 8-dihydro-2′-deoxyguanosine and biopyrrins levels among construction workers with asbestos exposure history. Ind Health 2001;39:186-8.
37. Tsukahara H, Shibata R, Ohshima Y, et al. Oxidative stress and altered antioxidant defenses in children with acute exacerbation of atopic dermatitis. Life Sci 2003;72:2509-16.
38. Vogt BA, Shanley TP, Croatt A, et al. Glomerular inflammation induces resistance to tubular injury in the rat. A novel form of acquired, heme-oxygenase-dependent resistance to renal injury. J Clin Invest 1996;98:2139-45.
39. Yang L, Quan S, Abraham NG. Retrovirus-mediated HO gene transfer into endothelial cells protects against oxidant-induced injury. Am J Physiol 1999;277:L127-33.
40. Bennaars-Eiden A, Higgins L, Hertzel AV, et al. Covalent modification of epithelial fatty acid-binding protein by 4-hydroxynonenal in vitro and in vivo. Evidence for a role in antioxidant biology. J Biol Chem 2002;277:50693-702.
41. Kanda T, Fujii H, Fujita M, et al. Intestinal fatty acid binding protein is available for diagnosis of interstitial ischaemia: immunochemical analysis of two patients with ischaemic intestinal diseases. Gut 1995;36:788-91.
42. van Nieuwenhoven FA, Kleine AH, Wodzig WH, et al. Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid-binding protein. Circulation 1995;92:2848-54.
43. Kamijo A, Kimura K, Sugaya T, et al. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004;143:23-30.
44. Kashiwagi A, Asahina T, Ikebuchi M, et al. Glycation, oxidative stress, and scavenger activity: glucose metabolism and radical scavenger dysfunction in endothelial cells. Diabetes 1996;45 Suppl 3:884-6.
45. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 1999;13:23-30.
46. Williams B, Schrier JW. Glucose-induced protein kinase C activity regulates arachidon acid release and eicosanoid production by cultured mesangial cells. J Clin Invest 1993;92:2889-96.
47. Haneda M, Araki S, Togawa M, et al. Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 1997;46:847-53.
48. Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003;14(8 Suppl 3):S254-8.
49. Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycoaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995;270:10017-26.
50. Brodsky SV, Gealekman O, Chen J, et al. Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. Circ Res 2004;94:377-84.
51. Ting HH, Timimi FK, Boles KS, et al. Vitamin C improves endothelium-dependent vasodilatation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996;97:22-8.
52. Giugliano D, Marfella R, Verrazzo G, et al. Abnormal rheologic effects of glyceryl trinitrate in patients with non-insulin-dependent diabetes mellitus and reversal by antioxidants. Ann Intern Med 1995;123:338-43.
53. Beckmann JS, Ye YZ, Anderson PG, et al. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler 1994;375:81-8.
54. Ceriello A, Mercuri F, Quagliaro L, et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001;44:834-8.
55. Aydin A, Orhan H, Sayal A, et al. Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control. Clin Biochem 2001;34:65-70.
56. Dominguez C, Ruiz E, Gussinye M, et al. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. Diabetes Care 1998;21:1736-42.
57. Elhadd TA, Kennedy G, Hill A, et al. Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with type 1 diabetes with no clinical vascular disease. Diabetes Metab Res Rev 1999;15:405-11.
58. Telci A, Cakatay U, Salman S, et al. Oxidative protein damage in early stage type 1 diabetic patients. Diabetes Res Clin Pract 2000;50:213-23.
59. Schiekofer S, Balletshofer B, Andrassy M, et al. Endothelial dysfunction in diabetes mellitus. Semin Thromb Hemost 2000;26:503-11.
60. Pomilio M, Mohn A, Verrotti A, Chiarelli F. Endothelial dysfunction in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002;15:343-61.
61. Suzuki D, Miyata T, Saotome N, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999;10:822-32.